203 related articles for article (PubMed ID: 28972043)
21. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
22. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
[TBL] [Abstract][Full Text] [Related]
23. Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer.
Holm J; Yu NY; Johansson A; Ploner A; Hall P; Lindström LS; Czene K
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442660
[TBL] [Abstract][Full Text] [Related]
24. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
25. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Falato C; Tobin NP; Lorent J; Lindström LS; Bergh J; Foukakis T
Mol Oncol; 2016 Apr; 10(4):517-25. PubMed ID: 26651914
[TBL] [Abstract][Full Text] [Related]
26. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.
Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Fu P; Honda Y; Iyama K; Iwase H
Mod Pathol; 2013 Jan; 26(1):79-86. PubMed ID: 22918168
[TBL] [Abstract][Full Text] [Related]
27. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
[TBL] [Abstract][Full Text] [Related]
28. Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Buus R; Yeo B; Brentnall AR; Klintman M; Cheang MCU; Khabra K; Sestak I; Gao Q; Cuzick J; Dowsett M
Breast Cancer Res; 2018 Sep; 20(1):103. PubMed ID: 30180877
[TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
[TBL] [Abstract][Full Text] [Related]
30. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
31. Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.
Tobin NP; Lindström LS; Carlson JW; Bjöhle J; Bergh J; Wennmalm K
Mol Oncol; 2014 May; 8(3):741-52. PubMed ID: 24630985
[TBL] [Abstract][Full Text] [Related]
32. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.
Vallon-Christersson J; Häkkinen J; Hegardt C; Saal LH; Larsson C; Ehinger A; Lindman H; Olofsson H; Sjöblom T; Wärnberg F; Ryden L; Loman N; Malmberg M; Borg Å; Staaf J
Sci Rep; 2019 Aug; 9(1):12184. PubMed ID: 31434940
[TBL] [Abstract][Full Text] [Related]
33. Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients.
de Kruijf EM; Bastiaannet E; Rubertá F; de Craen AJ; Kuppen PJ; Smit VT; van de Velde CJ; Liefers GJ
Mol Oncol; 2014 Jul; 8(5):1014-25. PubMed ID: 24767310
[TBL] [Abstract][Full Text] [Related]
34. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Dowsett M; Sestak I; Lopez-Knowles E; Sidhu K; Dunbier AK; Cowens JW; Ferree S; Storhoff J; Schaper C; Cuzick J
J Clin Oncol; 2013 Aug; 31(22):2783-90. PubMed ID: 23816962
[TBL] [Abstract][Full Text] [Related]
35. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
Guiu S; Michiels S; André F; Cortes J; Denkert C; Di Leo A; Hennessy BT; Sorlie T; Sotiriou C; Turner N; Van de Vijver M; Viale G; Loi S; Reis-Filho JS
Ann Oncol; 2012 Dec; 23(12):2997-3006. PubMed ID: 23166150
[TBL] [Abstract][Full Text] [Related]
36. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
37. The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer.
Naoi Y; Tsunashima R; Shimazu K; Noguchi S
Cancer Sci; 2021 Apr; 112(4):1369-1375. PubMed ID: 33544932
[TBL] [Abstract][Full Text] [Related]
38. Predicting OncoDX recurrence scores with immunohistochemical markers: effect of stromelysin.
Bradshaw SH; Pidutti D; Gravel DH; Song X; Robertson SJ
Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):26-30. PubMed ID: 25153499
[TBL] [Abstract][Full Text] [Related]
39. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
40. A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
Prat A; Lluch A; Turnbull AK; Dunbier AK; Calvo L; Albanell J; de la Haba-Rodríguez J; Arcusa A; Chacón JI; Sánchez-Rovira P; Plazaola A; Muñoz M; Paré L; Parker JS; Ribelles N; Jimenez B; Bin Aiderus AA; Caballero R; Adamo B; Dowsett M; Carrasco E; Martín M; Dixon JM; Perou CM; Alba E
Clin Cancer Res; 2017 Jun; 23(12):3035-3044. PubMed ID: 27903675
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
